PILIHAN TERAPI TERKINI PRURIGO NODULARIS
DOI:
https://doi.org/10.33820/mdvi.v48i2.151Abstract
Nodus hiperkeratotik yang sangat gatal dengan awitan kronis dan dapat mengganggu kualitas hidup merupakan karakteristik prurigo nodularis. Diagnosis PN berdasarkan penilaian klinis saja tidak sulit dilakukan namun perlu dicari etiologi atau penyakit yang mendasari. Oleh karena itu, dibutuhkan algoritma untuk menegakkan diagnosis prurigo nodularis. Saat ini terapi prurigo nodularis terdiri atas kortikosteroid topikal, capsaicin, penghambat kalsineurin, fototerapi, dan obat sistemik misalnya gabapentin, antidepresan, serta imunosupresan. Konsep pengobatan prurigo nodularis yang terkini antara lain pemberian opioid receptor antagonist, neurokinin-1 receptor antagonists, dan anti IL-4 telah dikembangkan, didukung berbagai uji klinis.
Downloads
Download data is not yet available.
References
1. Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019;80(3):756–64.
2. Silverberg JI. Nummular eczema, lichen simplex chronicus, and prurigo nodularis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel JD, Wolff K, editor. Fitzpatrick’s dermatology in general medicine. 9th Edition. New York: McGraw-Hill; 2018. p.385–94.
3. Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163–72.
4. Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic workup and evaluation of patients with prurigo nodularis. Medicines. 2019;6(4):E97.
5. Zeidler C, Yosipovitch G, Stander S. Prurigo nodularis and its management. Dermatol Clin. 2018;36(3):189–197.
6. Stander HF, Elmariah S, Zeidler C, Spellman M, Stander S. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2020;82(2):460–68.
11
7. Vornicescu C, Senila SC, Cosgarea R, Candrea E, Pop AD, Ungureanu L. Pemphigoid nodularis-rare presentation of bullous pemphigoid: A case report and literature review. Exp Ther Med. 2019;17(2):1132–8.
8. Cuevas-Gonzalez JC, Vega-Memije ME, Borges-Yanez SA, Rodriguez-Lobato E. Risk factors associated with actinic prurigo: a case control study. An Bras Dermatol. 2017;92(6):774–8.
9. Ankad BS, Beergourder SL. Hypertropic lichen planus versus prurigo nodularis: a dermoscopic perspective. Dermatol Pract Concept. 2016;6(2):9–15.
10. Saraceno R, Chiricozzi A, Nistico SP, Tiberti S, Chimenti S. An occlusive dressing containing betamethasone valerate 0,1% for the treatment of prurigo nodularis. J Dermatolog Treat. 2010;21(6):363–6
11. Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, Butterfass-Bahloul T, et al. Evaluation of the antipruritic effects of the topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized hydrocortisone-controlled, double-blind phase II trial. 2013;227(4):353–60.
12. Klejtman T, Beylot-Barry M, Joly P, Richard MA, Debarbieux S, Misery L, Wolkenstein P, et al. Treatment of prurigo with methotrexated: a multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol. 2018;32(3):437–40.
13. Spring P, Gschwind I, Gilliet M. Prurigo nodularis retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol. 2014;39(4):468–73.
14. Siepmann D, Luger TA, Stander S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges. 2008;6(11):941–6.
15. Zeidler C, Tsianakas A, Pereira M, Stander H, Yosipovitch G, Stander S. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173–9.
16. Sardaa K, Gupta A, Sinha S. An observasional analysis of low-dose thalidomide in recalcitrant prurigo nodularis. Clin Exp Dermatol. 2020;45(1):92–6.
17. Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification, and terminology of chronic prurigo. J Eur Acad Dermatol Venereol.
2018;32(7):1059–1065.
18. Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S. Treatment of prurigo nodularis
with pregabalin. J Clin Pharm Ther. 2013;38(1):16–8.
19. Stander S, Bockenholt B, Schurmeyer-Horst F, Weishaupt C, Heuft G, Luger Ta, et al.
Treatment of chronic pruritus with the selective serotonin reuptake inhibitors paroxetine and fluvoxamine: results of an open labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89(1):45–51.
20. Shintani T, Ohata C, Koga H, Ohyama B, Hamada T, Nakama T, et al. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatol Ther. 2014;27(3):135–9.
21. Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol. 2010;35(5):549–50.
22. Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol. 2007;34(10):691–5
23. Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.
24. Ohanyan T, Schoepke N, Eirefelt S, Hoey G, Koopmann W, Hawro T, et al. Roles of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. Acta Derma Venereol. 2018;98(1):26–31.
25. Stander S, Kwon P, Hirman J, Perlman AJ, Weisshaar E, Metz M, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019;80(5):1395–1402.
26. Smith HB. A phase 2b/3 randomized, double-blind, placebo-controlled, 2-arm, efficacy and safety study in prurigo nodularis with nalbuphine ER tablets for pruritus relief through itch scratch modulation. 2016.
27. Lee J, Shin JU, Noh S, Park CO, Lee KH. Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus. Ann Dermatol. 2016;28(2):159–63.
28. Holm JG, Agner T, Sand C, Thomsen SF. Dupilumab for prurigo nodularis; case series and review of the literature. Dermatol Ther. 2020;9:e13222.
29. Calugareanu A, Jachiet M, Tauber M, Nosbaum A, Aubin F, Misery L. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicentre adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34(2):e74–e76.
30. Pereira MP, Basta S, Moore J, Stander S. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet neet. J Eur Acad Dermatol Venereol. 2018;32(12):2224–9.
2. Silverberg JI. Nummular eczema, lichen simplex chronicus, and prurigo nodularis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffel JD, Wolff K, editor. Fitzpatrick’s dermatology in general medicine. 9th Edition. New York: McGraw-Hill; 2018. p.385–94.
3. Kowalski EH, Kneiber D, Valdebran M, Patel U, Amber KT. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163–72.
4. Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic workup and evaluation of patients with prurigo nodularis. Medicines. 2019;6(4):E97.
5. Zeidler C, Yosipovitch G, Stander S. Prurigo nodularis and its management. Dermatol Clin. 2018;36(3):189–197.
6. Stander HF, Elmariah S, Zeidler C, Spellman M, Stander S. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2020;82(2):460–68.
11
7. Vornicescu C, Senila SC, Cosgarea R, Candrea E, Pop AD, Ungureanu L. Pemphigoid nodularis-rare presentation of bullous pemphigoid: A case report and literature review. Exp Ther Med. 2019;17(2):1132–8.
8. Cuevas-Gonzalez JC, Vega-Memije ME, Borges-Yanez SA, Rodriguez-Lobato E. Risk factors associated with actinic prurigo: a case control study. An Bras Dermatol. 2017;92(6):774–8.
9. Ankad BS, Beergourder SL. Hypertropic lichen planus versus prurigo nodularis: a dermoscopic perspective. Dermatol Pract Concept. 2016;6(2):9–15.
10. Saraceno R, Chiricozzi A, Nistico SP, Tiberti S, Chimenti S. An occlusive dressing containing betamethasone valerate 0,1% for the treatment of prurigo nodularis. J Dermatolog Treat. 2010;21(6):363–6
11. Siepmann D, Lotts T, Blome C, Braeutigam M, Phan NQ, Butterfass-Bahloul T, et al. Evaluation of the antipruritic effects of the topical pimecrolimus in non-atopic prurigo nodularis: results of a randomized hydrocortisone-controlled, double-blind phase II trial. 2013;227(4):353–60.
12. Klejtman T, Beylot-Barry M, Joly P, Richard MA, Debarbieux S, Misery L, Wolkenstein P, et al. Treatment of prurigo with methotrexated: a multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol. 2018;32(3):437–40.
13. Spring P, Gschwind I, Gilliet M. Prurigo nodularis retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol. 2014;39(4):468–73.
14. Siepmann D, Luger TA, Stander S. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges. 2008;6(11):941–6.
15. Zeidler C, Tsianakas A, Pereira M, Stander H, Yosipovitch G, Stander S. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173–9.
16. Sardaa K, Gupta A, Sinha S. An observasional analysis of low-dose thalidomide in recalcitrant prurigo nodularis. Clin Exp Dermatol. 2020;45(1):92–6.
17. Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification, and terminology of chronic prurigo. J Eur Acad Dermatol Venereol.
2018;32(7):1059–1065.
18. Mazza M, Guerriero G, Marano G, Janiri L, Bria P, Mazza S. Treatment of prurigo nodularis
with pregabalin. J Clin Pharm Ther. 2013;38(1):16–8.
19. Stander S, Bockenholt B, Schurmeyer-Horst F, Weishaupt C, Heuft G, Luger Ta, et al.
Treatment of chronic pruritus with the selective serotonin reuptake inhibitors paroxetine and fluvoxamine: results of an open labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89(1):45–51.
20. Shintani T, Ohata C, Koga H, Ohyama B, Hamada T, Nakama T, et al. Combination therapy of fexofenadine and montelukast is effective in prurigo nodularis and pemphigoid nodularis. Dermatol Ther. 2014;27(3):135–9.
21. Bruni E, Caccialanza M, Piccinno R. Phototherapy of generalized prurigo nodularis. Clin Exp Dermatol. 2010;35(5):549–50.
22. Tamagawa-Mineoka R, Katoh N, Ueda E, Kishimoto S. Narrow-band ultraviolet B phototherapy in patients with recalcitrant nodular prurigo. J Dermatol. 2007;34(10):691–5
23. Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968.
24. Ohanyan T, Schoepke N, Eirefelt S, Hoey G, Koopmann W, Hawro T, et al. Roles of substance P and its receptor neurokinin 1 in chronic prurigo: a randomized, proof-of-concept, controlled trial with topical aprepitant. Acta Derma Venereol. 2018;98(1):26–31.
25. Stander S, Kwon P, Hirman J, Perlman AJ, Weisshaar E, Metz M, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019;80(5):1395–1402.
26. Smith HB. A phase 2b/3 randomized, double-blind, placebo-controlled, 2-arm, efficacy and safety study in prurigo nodularis with nalbuphine ER tablets for pruritus relief through itch scratch modulation. 2016.
27. Lee J, Shin JU, Noh S, Park CO, Lee KH. Clinical efficacy and safety of naltrexone combination therapy in older patients with severe pruritus. Ann Dermatol. 2016;28(2):159–63.
28. Holm JG, Agner T, Sand C, Thomsen SF. Dupilumab for prurigo nodularis; case series and review of the literature. Dermatol Ther. 2020;9:e13222.
29. Calugareanu A, Jachiet M, Tauber M, Nosbaum A, Aubin F, Misery L. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicentre adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34(2):e74–e76.
30. Pereira MP, Basta S, Moore J, Stander S. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet neet. J Eur Acad Dermatol Venereol. 2018;32(12):2224–9.
Downloads
Published
2021-10-13
How to Cite
Respati, R. A., & Budianti, W. K. (2021). PILIHAN TERAPI TERKINI PRURIGO NODULARIS. Media Dermato-Venereologica Indonesiana, 48(2). https://doi.org/10.33820/mdvi.v48i2.151
Issue
Section
Tinjauan Pustaka
